^
    Back
    Association details:
    Biomarker:EGFR T790M
    Cancer:Lung Adenocarcinoma
    Drug:gefitinib (EGFR inhibitor) +
    Ogsiveo (nirogacestat) (γ-secretase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Clin Invest
    Title:

    Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma

    Published date:
    02/03/2020
    Excerpt:
    ...the combination of gefitinib and nirogacestat increases the survival of mice xenografted with human lung adenocarcinoma cells that carry the EGFRT790M mutation conferring resistance to EGFR TKIs.
    DOI:
    10.1172/JCI126896